

09PH  
K139



# **IMMUNE RESPONSE TO ENZYME REPLACEMENT THERAPY IN MPS I AND GSD II PATIENTS**

---

By

**Revecca Kakavanos**

B.Sc. (Hons)

Faculty of Health Sciences

Department of Paediatrics



This thesis is submitted for the degree of Doctor of Philosophy

February, 2006

# TABLE OF CONTENTS

<b>Thesis Summary</b> .....	<b>i</b>
<b>Declaration</b> .....	<b>iv</b>
<b>Acknowledgements</b> .....	<b>v</b>
<b>List of Abbreviations</b> .....	<b>vi</b>
<b>List of Figures</b> .....	<b>viii</b>
<b>List of Tables</b> .....	<b>xi</b>
<b>Publications arising from this study</b> .....	<b>xii</b>
<b>Chapter 1: Introduction</b> .....	<b>1</b>
1.1 <i>The lysosome and the endocytic network</i> .....	2
1.1.1 Synthesis of lysosomal hydrolases and delivery to the lysosome .....	4
1.2 <i>LSD</i> .....	5
1.2.1 Prevalence and genetics of LSD .....	6
1.2.2 Clinical presentation .....	10
1.2.3 Diagnosis of LSD.....	12
1.3 <i>GSD II</i> .....	14
1.3.1 History of GSD II .....	14
1.3.2 GSD II clinical phenotype .....	16
1.3.2.1 Infantile-onset GSD II .....	17
1.3.2.2 Juvenile-onset GSD II.....	19
1.3.2.3 Adult-onset GSD II.....	20
1.3.3 Diagnosis of GSD II .....	20
1.3.4 Genetics of GSD II .....	22
1.3.5 Protein synthesis and post translational processing of $\alpha$ -D-glucosidase .....	23
1.4 <i>MPS I</i> .....	24
1.4.1 Clinical phenotype of MPS I .....	26
1.4.1.1 Hurler syndrome .....	26
1.4.1.2 Hurler-Scheie syndrome .....	28
1.4.1.3 Scheie syndrome .....	28
1.4.2 Genetics of MPS I.....	28
1.4.3 Diagnosis of MPS I.....	30
1.4.4 Protein synthesis and post-translational processing of $\alpha$ -L-iduronidase .....	31
1.5 <i>Therapy for LSD</i> .....	31
1.5.1 <i>In vitro</i> studies of ERT in MPS I and GSD II.....	37
1.5.2 Preclinical and clinical trials of ERT in GSD II .....	38
1.5.3 Preclinical and clinical trials of ERT in MPS I .....	41
1.6 <i>Immune response to ERT</i> .....	42
1.6.1 Measures of an immune response .....	42
1.6.2 Frequency of immune response in ERT-treated LSD animals and patients .....	43
1.6.3 Adverse effects of antibody production.....	46
1.6.4 Antibody effects on ERT efficacy .....	48
1.6.5 Significance of immune response to ERT .....	51
1.7 <i>Hypothesis and aims</i> .....	53

<b>Chapter 2: Materials and Methods .....</b>	<b>54</b>
2.1 <i>Materials</i> .....	55
2.2 <i>Tissue culture</i> .....	56
2.2.1 Culture of CHO cells .....	56
2.2.1.1 rh- $\alpha$ -D-Glucosidase expression with and without additional D-glucose .56	
2.2.1.2 Expression of rh- $\alpha$ -D-glucosidase, rh- $\alpha$ -L-iduronidase and rh-4-sulphatase.....	57
2.2.2 Culture of GSD II patient skin fibroblasts in the presence of D-glucose.....	57
2.2.3 Cell harvesting .....	58
2.2.4 Cell lysate preparation .....	58
2.2.5 Culture of hybridoma cell lines .....	59
2.2.6 Cryopreservation of hybridoma, fibroblast and CHO-K1 cells.....	59
2.2.7 Thawing of cryopreserved hybridoma, skin fibroblast or CHO-K1 cells....	59
2.3 <i>Immune assays</i> .....	60
2.3.1 Evaluation of sera samples for antibody titre .....	60
2.3.2 Epitope mapping .....	61
2.3.3 Temperature denaturation of $\alpha$ -D-glucosidase .....	62
2.3.4 Immune quantification assay for lysosomal proteins .....	64
2.3.5 Multiplex analysis of lysosomal proteins .....	65
2.4 <i>Infusion of rh-<math>\alpha</math>-D-glucosidase into animal models</i> .....	66
2.4.1 rh- $\alpha$ -D-Glucosidase immunised rats .....	66
2.4.2 Subcutaneous infusion of rh- $\alpha$ -D-glucosidase in mice.....	67
2.5 <i>Blood collection and sera sample preparation</i> .....	67
2.5.1 Heart puncture.....	67
2.5.2 Tail vein blood sampling from rats and mice .....	68
2.5.3 Preparation of ovalbumin/BSA-bound Affi-Gel 10.....	68
2.5.4 Albumin absorption of sera samples.....	69
2.6 <i>rh-<math>\alpha</math>-D-Glucosidase purification from CHO-K1 expression cells</i> .....	69
2.6.1 rh- $\alpha$ -D-Glucosidase purification.....	69
2.6.2 Modified rh- $\alpha$ -D-glucosidase purification.....	70
2.7 <i>Enzyme activity assays</i> .....	71
2.7.1 $\alpha$ -D-Glucosidase activity .....	71
2.7.2 $\alpha$ -L-Iduronidase activity .....	71
2.7.3 4-Sulphatase activity.....	72
2.7.4 Enzyme inhibition studies.....	72
2.8 <i>Protein estimation</i> .....	73
2.8.1 BCA method for protein determination .....	73
2.8.2 Lowry method for protein determination.....	73
2.9 <i>Western blot analysis</i> .....	74
<b>Chapter 3: Immune reactivity in MPS I.....</b>	<b>76</b>
3 <i>Introduction</i> .....	77
3.1 <i>Results</i> .....	77
3.1.1 Antibody response in rh- $\alpha$ -L-iduronidase-treated mice.....	77
3.1.2 Antibody titres to rh- $\alpha$ -L-iduronidase in ERT treated MPS I patients .....	79
3.1.3 Epitope reactivity of ERT treated MPS I patient sera antibodies .....	81

3.2	<i>Discussion</i> .....	89
<b>Chapter 4: Glycosidase cross reactivity</b> .....		<b>94</b>
4	<i>Introduction</i> .....	95
4.1	<i>Results</i> .....	97
4.1.1	Epitope reactivity of $\alpha$ -D-glucosidase and $\alpha$ -L-iduronidase polyclonal antibodies .....	97
4.1.1.1	Antibody reactivity to native and denatured forms of rh- $\alpha$ -D-glucosidase . .....	99
4.1.2	Epitope reactivity of monoclonal antibodies to $\alpha$ -D-glucosidase .....	99
4.1.3	Effect of temperature on monoclonal antibody reactivity to $\alpha$ -D-glucosidase .....	102
4.1.4	Antibody titres to rh- $\alpha$ -D-glucosidase in four immunised rats .....	105
4.1.4.1	Epitope reactivity of immunised rat sera antibodies.....	105
4.1.5	Epitope cross-reactivity of $\alpha$ -D-glucosidase and $\alpha$ -L-iduronidase antibodies. .....	112
4.1.6	Analysis of antigenic motifs that had sequence identity.....	114
4.2	<i>Discussion</i> .....	117
<b>Chapter 5: Effect of D-glucose on <math>\alpha</math>-D-glucosidase expression, purification and antibody reactivity</b> .....		<b>123</b>
5	<i>Introduction</i> .....	124
5.1	<i>Results</i> .....	125
5.1.1	Differential rh- $\alpha$ -D-glucosidase expression in media.....	125
5.1.1.1	The affect of increasing D-glucose concentration on rh- $\alpha$ -D-glucosidase expression .....	128
5.1.1.2	Effect of sugar and butyric acid on rh- $\alpha$ -D-glucosidase, rh- $\alpha$ -L- iduronidase and rh-4-sulphatase expression .....	128
5.1.2	Inhibition studies for two glycosidase enzymes .....	133
5.1.2.1	Effect of monosaccharide on purified rh- $\alpha$ -D-glucosidase.....	133
5.1.2.2	Comparison of rh- $\alpha$ -D-glucosidase inhibition by D-glucose .....	135
5.1.2.3	Inhibition of rh- $\alpha$ -L-iduronidase by D-glucose.....	135
5.1.3	Improved yield of rh- $\alpha$ -D-glucosidase from CHO-K1 cell cultures treated with D-glucose .....	139
5.1.4	Effect of D-glucose on $\alpha$ -D-glucosidase activity in GSD II patient skin fibroblasts.....	142
5.1.5	Differential antigenicity of rh- $\alpha$ -D-glucosidase from transgenic rabbit milk and a CHO-K1 cell line .....	142
5.1.5.1	Antigenicity of rh- $\alpha$ -D-glucosidase in enzyme-treated animals .....	142
5.1.5.2	Epitope reactivity of serum antibodies from mice treated with rh- $\alpha$ -D- glucosidase.....	145
5.1.6	Reduction of antibody reactivity to rh- $\alpha$ -D-glucosidase in the presence of D- glucose .....	148
5.2	<i>Discussion</i> .....	152
<b>Chapter 6: Concluding discussion</b> .....		<b>158</b>
<b>References</b> .....		<b>172</b>

## THESIS SUMMARY

Enzyme replacement therapy (ERT) has been shown to be an effective treatment strategy for a number of lysosomal storage diseases (LSD's) in both animal models and in human clinical trials. Immune response to replacement proteins however has been reported for a number of LSD and can be a potential complication for therapy. Immune responses to ERT are variable and dependent on both the inherent antigenicity of the protein being infused and the individual patient. I have investigated the immune reactivity of two lysosomal glycosidases,  $\alpha$ -D-glucosidase and  $\alpha$ -L-iduronidase. Functional deficiencies of these lysosomal enzymes are the cause of the LSD Glycogen storage disease type II (GSD II) and mucopolysaccharidosis type I (MPS I) respectively.

In a phase I/II clinical trial of ERT in MPS I patients, an immune response to  $\alpha$ -L-iduronidase was observed in 50% of patients. The MPS I patients that initially had an immune response were shown in this thesis, to develop natural immune-tolerance to  $\alpha$ -L-iduronidase after a year of ERT. This finding has positive implications for MPS I patients who are undergoing long term ERT. A specific peptide that mapped to the catalytic element of  $\alpha$ -L-iduronidase also appeared to be important in the development and maintenance of the immune response to  $\alpha$ -L-iduronidase. In defining sites on the replacement protein, to which antibodies react, ways to improve ERT by minimising or eliminating antibody reactivity may be engineered.

It was postulated that the conservation of structural features in the active sites of glycosidases using a retaining catalytic mechanism, might result in common antigenicity. This study demonstrated that despite limited sequence identity between  $\alpha$ -L-iduronidase and  $\alpha$ -D-glucosidase, conserved micro-structural features and regions of short sequence

identity could make a major contribution to common glycosidase antigenicity. This common antigenicity in related glycosidases may contribute some background immune reactivity, representative of the major antigenic sites on the missing glycosidase and may account for why immune response to ERT has proven to be less of an issue than initially postulated.

A high incidence of antibody production to the rh- $\alpha$ -D-glucosidase replacement protein has been reported in the literature for GSD II patients treated by ERT. Furthermore, relative to other LSD types, large doses of rh- $\alpha$ -D-glucosidase are required for effective ERT in GSD II patients. In this thesis, the  $\alpha$ -D-glucosidase catalytic site was identified as one of the main antigenic regions of this lysosomal protein. It was postulated that stabilising the catalytic site of  $\alpha$ -D-glucosidase could increase the amount of protein recovered during purification and partially mask antibody reactivity against this region. This study demonstrated that D-glucose stabilised  $\alpha$ -D-glucosidase allowing increased expression and improved purification of the recombinant protein from an over-expressing CHO-K1 cell line. This simple strategy could accommodate the high demand of enzyme required for ERT studies. D-Glucose also enhanced the residual  $\alpha$ -D-glucosidase protein/activity in adult-onset GSD II patient cells suggesting the development of D-glucose analogues may be beneficial as an enzyme enhancement therapy for adult-onset GSD II patients. Furthermore, D-glucose-treated rh- $\alpha$ -D-glucosidase had reduced antibody reactivity *in vitro* suggesting that it may also be useful as a modifier of the immune response to ERT in GSD II patients. These findings have positive implications for ERT in GSD II patients.

When considering the safety and efficacy of ERT in LSD patients, it is important to know when an immune response develops, and whether it is maintained over the course of

treatment. It is clear that some LSD patients will develop antibodies against ERT and now there is also some evidence to suggest that these could compromise the health of the patient and therapy efficacy. Therefore, characterising these immune responses becomes crucial for the management of patients receiving long term ERT. An increased understanding of antibody development in enzyme treated LSD patients will aid in engineering ways to avert the potential affects of antibody production and will assist in the delivery of a more effective and safe therapy.